NFL Biosciences Reveals 2024 Results and Updates Clinical Progress

NFL Biosciences, a biopharmaceutical company based in Montpellier, presented its 2024 financial results and clinical advancements. Key progress includes the development of NFL-101, a pioneering treatment for smoking cessation. Phase 2 studies confirmed its efficacy and safety, showing promise for the planned Phase 3 trial.

The company aims to fund the first part of the Phase 3 trial, with a budget of €5 million, through partnerships or non-dilutive financing. NFL Biosciences maintains financial visibility until early Q4 2025, with ongoing discussions to support the clinical program.

Financially, NFL Biosciences reported no net revenue for 2024, an improvement in EBIT, and a net income of (2,080) k€, reflecting focused R&D spending. The company's cash reserves stand at €1.9 million, underscoring the need for strategic financing and partnerships.